KyDo Therapeutics raises Undisclosed
KyDo Therapeutics announced a Seed round of Undisclosed on 9 November 2026. The company operates in HealthTech and is based in Germany. It was founded by Matthias Stein-Gerlach, CEO. Announced 3 days ago.
Founder
Matthias Stein-Gerlach
CEO, KyDo Therapeutics
Outreach angles
- -Matthias Stein-Gerlach is CEO of KyDo Therapeutics, which won the 2026 MATWIN award for the best drug-based innovation project in oncology.
- -KyDo was co-founded by Lead Discovery Center and scientists from Prof. Daniel Rauh's lab at TU Dortmund, building on covalent-allosteric inhibitor technology from that lab.
- -The additional seed financing from existing investors including i&i Biotech Fund, KHAN-II, VORNvc, TU capital and LDC follows a EUR 4.45M seed in September 2025 that is advancing lead inhibitors toward IND-enabling studies.
Signals
SeedHealthcareDeep TechRegulated Industry
Round details
Company: KyDo Therapeutics
Domain: kydo-tx.com
Amount: Undisclosed
Stage: Seed
Industry: HealthTech
Country: Germany
Announced: 9 November 2026
Other HealthTech raises
Recently funded in Germany